Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

Benjamin M. Stermole; Greg A. Grandits; Mollie P. Roediger; Brychan M. Clark; Anuradha Ganesan; Amy C. Weintrob; Nancy F. Crum-Cianflone; Tomas M. Ferguson; Grace E. Macalino; Michael L. Landrum

doi:10.1016/j.vaccine.2011.02.013

Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

Benjamin M. Stermole, Greg A. Grandits, Mollie P. Roediger, Brychan M. Clark, Anuradha Ganesan, Amy C. Weintrob, Nancy F. Crum-Cianflone, Tomas M. Ferguson, Grace E. Macalino, Michael L. Landrum

Biostatistics

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

We analyzed HIV viral load (VL) and CD4 count changes, and antibody responses following MMR vaccination of individuals in the U.S. Military HIV Natural History Study cohort. Cases receiving at least one dose of MMR vaccine after HIV diagnosis were matched 1:2 to HIV-positive controls not receiving the vaccine. Baseline was defined as time of vaccination for cases and indexed and matched to the time post-HIV diagnosis for controls. Changes in CD4 count and VL at 6, 12, 18 and 24 months were compared between cases and controls using a general linear model. Available sera from cases were tested for MMR seropositivity at baseline and post-vaccination at 6, 12, 18, and 24 months. Overall mean CD4 count change from baseline through 24 months was 20 (±23) cells/μL greater for cases than controls (p=0.39). Similar non-significant changes in CD4 cell count were seen in the subset of those not on HAART at baseline. VL changes were small and similar between groups (mean differential change -0.04 (±0.18) log₁₀ copies/mL; p=0.84). Of 21 vaccinated participants with baseline serologic testing, 14 (67%) were reactive to measles, 19 (91%) to mumps, and 20 (95%) to rubella. Three (43%) of 7 participants nonreactive to measles developed measles IgG; for mumps, 1 (50%) of 2 developed mumps IgG; for rubella, 1 (100%) developed rubella IgG. MMR vaccination did not result in detrimental immunologic or virologic changes through 24 months post-vaccination.

Original language	English (US)
Pages (from-to)	2874-2880
Number of pages	7
Journal	Vaccine
Volume	29
Issue number	16
DOIs	https://doi.org/10.1016/j.vaccine.2011.02.013
State	Published - Apr 5 2011

Bibliographical note

Funding Information:
Support for this work (IDCRP-000-10) was provided by the Infectious Disease Clinical Research Program (IDCRP) , a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072.

Keywords

Human immunodeficiency virus
MMR Vaccine
Measles
Mumps
Vaccination
Vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.vaccine.2011.02.013

OpenUrl availability

Full text

Cite this

@article{5fd174084222491d8670d40cd0db5dd2,

title = "Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults",

abstract = "We analyzed HIV viral load (VL) and CD4 count changes, and antibody responses following MMR vaccination of individuals in the U.S. Military HIV Natural History Study cohort. Cases receiving at least one dose of MMR vaccine after HIV diagnosis were matched 1:2 to HIV-positive controls not receiving the vaccine. Baseline was defined as time of vaccination for cases and indexed and matched to the time post-HIV diagnosis for controls. Changes in CD4 count and VL at 6, 12, 18 and 24 months were compared between cases and controls using a general linear model. Available sera from cases were tested for MMR seropositivity at baseline and post-vaccination at 6, 12, 18, and 24 months. Overall mean CD4 count change from baseline through 24 months was 20 (±23) cells/μL greater for cases than controls (p=0.39). Similar non-significant changes in CD4 cell count were seen in the subset of those not on HAART at baseline. VL changes were small and similar between groups (mean differential change -0.04 (±0.18) log10 copies/mL; p=0.84). Of 21 vaccinated participants with baseline serologic testing, 14 (67%) were reactive to measles, 19 (91%) to mumps, and 20 (95%) to rubella. Three (43%) of 7 participants nonreactive to measles developed measles IgG; for mumps, 1 (50%) of 2 developed mumps IgG; for rubella, 1 (100%) developed rubella IgG. MMR vaccination did not result in detrimental immunologic or virologic changes through 24 months post-vaccination.",

keywords = "Human immunodeficiency virus, MMR Vaccine, Measles, Mumps, Vaccination, Vaccines",

author = "Stermole, {Benjamin M.} and Grandits, {Greg A.} and Roediger, {Mollie P.} and Clark, {Brychan M.} and Anuradha Ganesan and Weintrob, {Amy C.} and Crum-Cianflone, {Nancy F.} and Ferguson, {Tomas M.} and Macalino, {Grace E.} and Landrum, {Michael L.}",

note = "Funding Information: Support for this work (IDCRP-000-10) was provided by the Infectious Disease Clinical Research Program (IDCRP) , a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072. ",

year = "2011",

month = apr,

day = "5",

doi = "10.1016/j.vaccine.2011.02.013",

language = "English (US)",

volume = "29",

pages = "2874--2880",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "16",

}

TY - JOUR

T1 - Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

AU - Stermole, Benjamin M.

AU - Grandits, Greg A.

AU - Roediger, Mollie P.

AU - Clark, Brychan M.

AU - Ganesan, Anuradha

AU - Weintrob, Amy C.

AU - Crum-Cianflone, Nancy F.

AU - Ferguson, Tomas M.

AU - Macalino, Grace E.

AU - Landrum, Michael L.

N1 - Funding Information: Support for this work (IDCRP-000-10) was provided by the Infectious Disease Clinical Research Program (IDCRP) , a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072.

PY - 2011/4/5

Y1 - 2011/4/5

N2 - We analyzed HIV viral load (VL) and CD4 count changes, and antibody responses following MMR vaccination of individuals in the U.S. Military HIV Natural History Study cohort. Cases receiving at least one dose of MMR vaccine after HIV diagnosis were matched 1:2 to HIV-positive controls not receiving the vaccine. Baseline was defined as time of vaccination for cases and indexed and matched to the time post-HIV diagnosis for controls. Changes in CD4 count and VL at 6, 12, 18 and 24 months were compared between cases and controls using a general linear model. Available sera from cases were tested for MMR seropositivity at baseline and post-vaccination at 6, 12, 18, and 24 months. Overall mean CD4 count change from baseline through 24 months was 20 (±23) cells/μL greater for cases than controls (p=0.39). Similar non-significant changes in CD4 cell count were seen in the subset of those not on HAART at baseline. VL changes were small and similar between groups (mean differential change -0.04 (±0.18) log10 copies/mL; p=0.84). Of 21 vaccinated participants with baseline serologic testing, 14 (67%) were reactive to measles, 19 (91%) to mumps, and 20 (95%) to rubella. Three (43%) of 7 participants nonreactive to measles developed measles IgG; for mumps, 1 (50%) of 2 developed mumps IgG; for rubella, 1 (100%) developed rubella IgG. MMR vaccination did not result in detrimental immunologic or virologic changes through 24 months post-vaccination.

AB - We analyzed HIV viral load (VL) and CD4 count changes, and antibody responses following MMR vaccination of individuals in the U.S. Military HIV Natural History Study cohort. Cases receiving at least one dose of MMR vaccine after HIV diagnosis were matched 1:2 to HIV-positive controls not receiving the vaccine. Baseline was defined as time of vaccination for cases and indexed and matched to the time post-HIV diagnosis for controls. Changes in CD4 count and VL at 6, 12, 18 and 24 months were compared between cases and controls using a general linear model. Available sera from cases were tested for MMR seropositivity at baseline and post-vaccination at 6, 12, 18, and 24 months. Overall mean CD4 count change from baseline through 24 months was 20 (±23) cells/μL greater for cases than controls (p=0.39). Similar non-significant changes in CD4 cell count were seen in the subset of those not on HAART at baseline. VL changes were small and similar between groups (mean differential change -0.04 (±0.18) log10 copies/mL; p=0.84). Of 21 vaccinated participants with baseline serologic testing, 14 (67%) were reactive to measles, 19 (91%) to mumps, and 20 (95%) to rubella. Three (43%) of 7 participants nonreactive to measles developed measles IgG; for mumps, 1 (50%) of 2 developed mumps IgG; for rubella, 1 (100%) developed rubella IgG. MMR vaccination did not result in detrimental immunologic or virologic changes through 24 months post-vaccination.

KW - Human immunodeficiency virus

KW - MMR Vaccine

KW - Measles

KW - Mumps

KW - Vaccination

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=79953224061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953224061&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.02.013

DO - 10.1016/j.vaccine.2011.02.013

M3 - Article

C2 - 21352938

AN - SCOPUS:79953224061

SN - 0264-410X

VL - 29

SP - 2874

EP - 2880

JO - Vaccine

JF - Vaccine

IS - 16

ER -

Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this